SCHEMBL3112397

SCHEMBL3112397

CCNC(=O)c1ccc(-n2nnc(C(=O)NC3CC3)c2COc2cccc(Cl)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 1/20 0.46
KLKB1 P03952 2/20 0.40
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 1/20 0.38
CHRM1 P11229 1/20 0.38
GABRA5 P31644 2/20 0.38
GRM5 P41594 1/20 0.38
DRD4 P21917 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
MCHR1 Q99705 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3099701 0.92 GABRA5 (0.39) SLC6A5RAB9ANPC1CYP1A2CYP2C9
SCHEMBL3117739 0.91 HPGD (0.46) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL3112516 0.91 POLB (0.47) RAB9ACYP1A2CYP2C9CYP2C19HPGD
SCHEMBL3107298 0.90 ROCK2 (0.43) RAB9ACYP2D6CYP2C9HPGDSMN1; SMN2
SCHEMBL3099680 0.90 GABRA5 (0.43) RAB9ACYP1A2CYP2C9CYP2C19HPGD
SCHEMBL3118127 0.90 KMT2A (0.44) RAB9ANPC1HPGDSMN1; SMN2GABRA5
SCHEMBL3104607 0.90 TP53 (0.46) SLC6A5NPC1SMN1; SMN2LMNARXFP1
SCHEMBL3114379 0.89 RXFP1 (0.44) SLC6A5RAB9ANPC1CYP1A2CYP2C9
SCHEMBL3116498 0.89 HPGD (0.44) RAB9ANPC1CYP1A2CYP2C9CYP2C19
SCHEMBL3111475 0.89 SLC6A5 (0.45) SLC6A5LMNAGABRA5MCHR1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 SLC6A5 2486/4885KLKB1 936/4885RAB9A 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.